Ames試驗用于檢測DNA損傷引起的基因突變。通過檢測受試物在測試菌株某些特殊構建的突變體上引起突變的能力，即造成菌株從組氨酸/色氨酸依賴型向原養型突變，判斷受試物是否為致突變劑。

Nonalcoholic steatohepatitis (NASH) is the advanced subtype of nonalcoholic fatty liver disease (NAFLD) and is becoming a severe global public health problem. PPARα/δ are regarded as potential therapeutic targets for NASH. Herein, researchers report a series of novel triazolone derivatives as PPARα/δ dual agonists. The pharmacokinetic studies were conducted by Medicilon. The hERG channel inhibition studies were conducted by Medicilon. The Ames tests were conducted by Medicilon.